Prof. Li Zhang
✓ Available through China Expert Care
Professor and PhD Supervisor; Deputy Director, Lung Cancer Research Institute, Sun Yat-sen University
Department of Medical Oncology, Sun Yat-sen University Cancer Center

Focus: Drug treatment of nasopharyngeal cancer and lung cancer, including chemotherapy and immunotherapy
Prof. Zhang has worked in medical oncology at Sun Yat-sen University Cancer Center for more than 40 years, with a focus on lung cancer and nasopharyngeal cancer. He was the first author of the phase III trial that established gemcitabine plus cisplatin as the standard first-line chemotherapy for recurrent or metastatic nasopharyngeal cancer. He is a senior consultant to the Center for Drug Evaluation of China's National Medical Products Administration.
Conditions: Nasopharyngeal cancer
Selected publications
- Lancet, 2016 (first author): Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. PubMed 27567279
- Lancet Oncology, 2021 (senior author): Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. PubMed 34174189
- Lancet Oncology, 2018 (senior author): Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. PubMed 30213452
Profile on the hospital website: https://english.sysucc.org.cn/info_26.aspx?itemid=417
Request a written opinion from Prof. Li Zhang
Send your records. A medical coordinator will reply within 24 hours.
Start here